ABSTRACT
The paper provides the results of differential neogilurythmal therapy in 20 patients with high-grade atrial and ventricular premature contractions in the presence of coronary heart disease. The detection of cardiac arrhythmias and evaluation of the antiarrhythmic efficacy of neogilurythmal were performed by Holter monitoring and transesophageal electrophysiological study. After the baseline studies, the antiarrhythmic efficacy of the drug was evaluated during an acute drug test and then during a 8-day course of the therapy. In the acute drug test, the dose of neogilurythmal was 50% of the daily dosage. The studies indicated that neogilurythmal in a dose of 80 mg/day was beneficial in affecting both the atrial and ventricular extrasystolic arrhythmia. The agent failed to alter heart rate, sinus nodal function and atrioventricular conduction. Thus, neogilurythmal is low toxic and produces no adverse effects when given in the definite dosage range.
Subject(s)
Cardiac Complexes, Premature/drug therapy , Prajmaline/therapeutic use , Adult , Cardiac Complexes, Premature/diagnosis , Cardiac Complexes, Premature/etiology , Child , Coronary Disease/complications , Electrocardiography , Female , Humans , Male , Middle Aged , Prajmaline/administration & dosage , Prajmaline/adverse effectsABSTRACT
Basing on the analysis of case histories and of laboratory and instrumental investigations of over 400 patients it is suggested to divide neurogenic myocardial dystrophies into 2 groups: primary-cortical (neurotic) and primary-hypothalamic with due consideration of clinical manifestations (vegetative-vascular and neuro-endocrine forms), running a crisis" course (sympathico-adrenal, vago-inular and mixed crises). Clinico-laboratory criteria of diagnosis and of differential diagnosis of separate forms of neurogenic myocardial dystrophies will help their timely detection and rational treatment, will serve to restore capacity for work in young and mature persons who represent almost a quarter of all patients with diseases of the cardio-vascular system. Successful treatment of neurogenic myocardial dystrophies is in a way a prophylaxis of ischaemic heart disease and hypertension, which supervene commonly enough in untreated or wrongly treated neurogenic myocardial dystrophies.
